ClinicalTrials.gg
RecruitingNCT07346521G-SCOGEUpdated Mar 9, 2026

Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy

An observational study in HELICOBACTER PYLORI INFECTIONS, Intestinal Metaplasia and Barett's Esophagus, sponsored by Sigmund Freud PrivatUniversitat. Recruiting at 1 site in Austria. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Sigmund Freud PrivatUniversitat · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
30 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn how common Helicobacter pylori (H. pylori) infection is in adults without stomach or upper gastrointestinal symptoms who are having a preventive screening colonoscopy.

Endoscopic screening of the stomach is yet not acceptet as a standard screening procedure in Western countries. However, Helicobacter pylori infection is known to increase the risk of developing gastric cancer.

This study will look at the prevalence of Helicobacter pylori infection in asymptomatic patients who have an additional gastroscopy during the same session as their screening colonoscopy. It will also record other early tissue changes or risk factors for stomach cancer, such as intestinal metaplasia and Barrett's mucosa.

The main questions this study aims to answer are:

  • How often is Helicobacter pylori found in adults without upper gastrointestinal symptoms by use of OGD?
  • Are there any correlations between H. pylori infection and other risk factors, such as BMI, smoking, alcohol consumption, or a family history of colorectal and/or stomach cancer?

About 1000 participants are expected to take part. Adults undergoing a screening colonoscopy at a private endoscopy center will be offered the chance to have an additional gastroscopy if they meet the study's inclusion criteria (no previous Helicobacter pylori infection and no upper gastrointestinal symptoms).

Small tissue samples (biopsies) will be taken from the stomach and lower esophagus during the gastroscopy. Biopsies will be checked histologically for the presence of Helicobacter pylori and early tissue changes.

During the gastroscopy, no additional procedures or biopsies will be done beyond what is normally performed during a routine examination. Everything done during this procedure follows the standard steps of a regular gastroscopy.

All data will be coded to protect participant privacy. Researchers will use statistical methods to find out how common Helicobacter pylori infection is and whether it is related to other lifestyle or family risk factors or tissue changes.

02

Conditions studied

  • HELICOBACTER PYLORI INFECTIONS
  • Intestinal Metaplasia
  • Barett's Esophagus

Browse trials for

03

In context

Metaplasia

45 studies on the registry are indexed under Metaplasia; 11 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 280 across 19 observational studies indexed under Metaplasia.

Browse Metaplasia studies →

Lead sponsor

Sigmund Freud PrivatUniversitat is the lead sponsor of 12 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Asymptomatic patients without upper gastrointestinal symptoms undergoing a Screening-Colonoscopy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 30 years
  • Scheduled screening colonoscopy (either initial screening or surveillance following previously detected polyps)
  • Asymptomatic (no gastrointestinal symptoms)
  • Willingness and consent to undergo simultaneous gastroscopy with sampling
  • Written to participate in the study, including the use of histological findings and patient data for study analysis

Exclusion criteria

Exclusion Criteria:

  • Known Helicobacter pylori infection or previous treatment for H. pylori
  • Current or recent proton pump inhibitor (PPI) therapy (\< 4 weeks)
  • Pre-existing gastrointestinal diseases (e.g., chronic gastritis, ulcer, gastric carcinoma)
  • or relevant underlying diseases
  • Refusal to undergo additional gastroscopy or
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asymptomatic patients undergoing Screening-Colonoscopy

    A synchronous gastroscopy performed during colonoscopy at the patient's request to detect Helicobacter pylori infection.

06

What researchers measure

Primary outcomes

  1. The number of asymptomatic patients who are Helicobacter-positive.

    All study participants undergo upper gastrointestinal endoscopy (gastroscopy). During the procedure, gastric biopsy specimens are obtained and subsequently processed for histopathological evaluation. The biopsies are analyzed to determine the presence of Helicobacter pylori infection. For statistical analysis, Helicobacter pylori status is coded as follows: absence of infection is recorded as 0, mild infection as 1, moderate infection as 2, and severe infection as 3.

    Time frame: From enrollment to the end of observation at 7 days

Secondary outcomes

  1. Asymptomatic patients who exhibit intestinal metaplasia and/or Barrett's mucosa.

    During gastroscopy, biopsy specimens are obtained according to standard endoscopic protocols. Gastric biopsies are histopathologically processed and evaluated for the presence of intestinal metaplasia and Barrett's esophagus. Biopsies obtained from the stomach (Sydney Biopsie Protocol) the ora serrata are likewise histologically examined to identify the presence of Barrett's esophagus and/or intestinal metaplasia.The overall objective of this analysis is to assess the correlation, as well as the strength of the association, between the primary outcome, Helicobacter pylori infection, and the secondary outcomes, namely intestinal metaplasia and Barrett's mucosa.

    Time frame: From enrollment to the end of observation at 7 days

Other outcomes

  1. Association of BMI, smoking, alcohol consumption, and family history with gastric- and colorectal cancer in relation to Helicobacter pylori infection

    The primary outcome of this study is the presence of Helicobacter pylori infection. Other pre-specified outcome measures include potential risk factors such as body mass index (BMI), smoking, alcohol consumption, and family history of gastric and colorectal cancer, all evaluated in relation to Helicobacter pylori. BMI is calculated based on self-reported weight (in kilograms) and height (in meters) using the standard formula: BMI = weight / (height²). Alcohol consumption and smoking habits are recorded through participant self-report, as is family history, which is assessed by asking whether there is a documented occurrence of gastric or colorectal cancer in first-degree relatives. These measures allow the analysis of correlations between Helicobacter pylori infection and established risk factors

    Time frame: From enrollment to the end of observation at 7 days

07

Study locations

1 of 1 sites recruiting
  • Wiener Privatklinik (WPK)
    Vienna, 1090, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Due to privacy regulations and restrictions of informed consent, de-identified individual participant data will not be made available. Additional Documents: Study protocol and statistical analysis plan may be provided upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: December 2025- December 2026 (12 months)

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 16, 2026
StartActual
Dec 16, 2025
Primary completionEst.
Dec 16, 2026
CompletionEst.
Dec 16, 2026
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07346521
Lead sponsor
Sigmund Freud PrivatUniversitat
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Dec 16, 2025
Primary completion
Dec 16, 2026 (estimated)
Completion
Dec 16, 2026 (estimated)
Last update
Mar 9, 2026

Study contacts

Harald Rosen, Univ. Prof. Dr.
Contact
rosensurg@csi.com
+43 664 4422571

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion